Skip to content
New issue

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

Sign up for GitHub

By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.

Already on GitHub? Sign in to your account

2024q4 updates and errors #14

Draft
wants to merge 1 commit into
base: main
Choose a base branch
from
+7 −7
Draft

2024q4 updates and errors #14

Changes from all commits
Commits
Show all changes
1 commit
Select commit
File filter

Filter by extension

Filter by extension
Conversations
Failed to load comments.
Loading
Jump to
Jump to file
Failed to load files.
Loading
Diff view
Diff view
14 changes: 7 additions & 7 deletions herpesdrg-db.tsv
View file
Open in desktop
Original file line number Diff line number Diff line change
Expand Up @@ -250,19 +250,19 @@ mutation_id virus genotype gene aa_change Ganciclovir Aciclovir Cidofovir Foscar
272 HCMV AD169 UL51 P91S 126 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP UL56 R369M 17/11/2019 OJCharles AD169 A
273 HCMV AD169 UL51 P91S 4 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP UL89 D344E 17/11/2019 OJCharles AD169 A
274 HCMV AD169 UL97 L337M 1 3.5 Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo https://www.sciencedirect.com/science/article/pii/S0166354212001283 doi.org/10.1016/j.antiviral.2012.05.013 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A
275 HCMV AD169 UL97 F342S 7.8 17 18 Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance https://aac.asm.org/content/aac/57/7/3375.full.pdf Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A
275 HCMV AD169 UL97 F342S 7.8 18 17 Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance https://aac.asm.org/content/aac/57/7/3375.full.pdf Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A
276 HCMV UL97 V353A 1 14 Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance https://academic.oup.com/jid/article/196/1/91/844651 doi.org/10.1086/518514 Marker Transfer SEAP 17/11/2019 OJCharles AD169 A
277 HCMV AD169 UL97 del355 16 23 304 Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance https://aac.asm.org/content/aac/57/7/3375.full.pdf Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A
278 HCMV AD169 UL97 V356G 5.5 7 108 Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance https://aac.asm.org/content/aac/57/7/3375.full.pdf Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A
277 HCMV AD169 UL97 del355 16 304 23 Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance https://aac.asm.org/content/aac/57/7/3375.full.pdf Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A
278 HCMV AD169 UL97 V356G 5.5 108 7 Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance https://aac.asm.org/content/aac/57/7/3375.full.pdf Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A
279 HCMV AD169 UL97 L397R 1.5 200 Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance https://academic.oup.com/jid/article-lookup/doi/10.1086/518514 doi.org/10.1086/518514 Marker Transfer SEAP 17/11/2019 OJCharles A
280 HCMV AD169 UL97 T409M 0.9 81 Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance https://academic.oup.com/jid/article/196/1/91/844651 doi.org/10.1086/518514 Marker Transfer SEAP 17/11/2019 OJCharles AD169 A
281 HCMV AD169 UL97 H411L 0.7 69 Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant https://jvi.asm.org/content/82/1/246.short doi.org/10.1128/JVI.01787-07 Marker transfer SEAP 17/11/2019 OJCharles AD169 A
282 HCMV AD169 UL97 H411N 1 9 Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant https://jvi.asm.org/content/82/1/246.short doi.org/10.1128/JVI.01787-07 Marker transfer SEAP 17/11/2019 OJCharles AD169 A
283 HCMV AD169 UL97 H411Y 0.5 12 Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant https://jvi.asm.org/content/82/1/246.short doi.org/10.1128/JVI.01787-07 Marker transfer SEAP 17/11/2019 OJCharles AD169 A
284 HCMV AD169 UL97 D456N 12 278 4.6 Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions https://journals.asm.org/doi/full/10.1128/aac.01726-13 doi.org/10.1128/aac.01726-13 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A
285 HCMV AD169 UL97 V466G 11 17 321 Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance https://aac.asm.org/content/aac/57/7/3375.full.pdf Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A
286 HCMV AD169 UL97 C480R 9 243 9 Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions https://journals.asm.org/doi/full/10.1128/aac.01726-13 doi.org/10.1128/aac.01726-13 Lab derived mutant PRA or SEAP 17/11/2019 OJCharles AD169 A
287 HCMV AD169 UL97 P521L 17 20 445 Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance https://aac.asm.org/content/aac/57/7/3375.full.pdf Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A
284 HCMV AD169 UL97 D456N 12 278 Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions https://journals.asm.org/doi/full/10.1128/aac.01726-13 doi.org/10.1128/aac.01726-13 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A
285 HCMV AD169 UL97 V466G 11 321 17 Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance https://aac.asm.org/content/aac/57/7/3375.full.pdf Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A
286 HCMV AD169 UL97 C480R 9 243 Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions https://journals.asm.org/doi/full/10.1128/aac.01726-13 doi.org/10.1128/aac.01726-13 Lab derived mutant PRA or SEAP 17/11/2019 OJCharles AD169 A
287 HCMV AD169 UL97 P521L 17 445 20 Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance https://aac.asm.org/content/aac/57/7/3375.full.pdf Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A
288 HCMV AD169 UL97 del617 10 372 22 Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions https://journals.asm.org/doi/full/10.1128/aac.01726-13 doi.org/10.1128/aac.01726-13 Lab derived mutant PRA or SEAP 17/11/2019 OJCharles AD169 A
289 HCMV AD169 UL97 V353A 1 227 Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant https://jvi.asm.org/content/82/1/246.short doi.org/10.1128/JVI.01787-07 Marker transfer SEAP UL97 H411L 17/11/2019 OJCharles AD169 A
290 HCMV AD169 UL97 V353A 0.7 164 Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant https://jvi.asm.org/content/82/1/246.short doi.org/10.1128/JVI.01787-07 Marker transfer SEAP UL97 H411Y 17/11/2019 OJCharles AD169 A
Expand Down